A new approach to tackling some of the most challenging proteins in cancer treatment is showing promise, with researchers developing protein-like polymers capable of degrading proteins long considered “undruggable.” The breakthrough, detailed in a recent study published in Nature Communications, offers a potential path forward for treating cancers driven by mutations in genes like MYC and KRAS. These proteins have historically resisted traditional drug development efforts due to their complex structures and roles within cells.
The research, spearheaded by Grove Biopharma, a private biotechnology company, centers around what they call “Bionic Biologics™”— a novel class of multifunctional biologics. These polymers are engineered to specifically target and dismantle disease-driving proteins, even those lacking well-defined binding pockets, a common hurdle in drug design. The study, published February 24, 2026, demonstrates the ability of these polymers to degrade MYC, a transcription factor implicated in approximately 70% of all human cancers and KRAS, a frequently mutated gene in various cancers. Business Wire reported on the findings.
The Challenge of ‘Undruggable’ Proteins
For decades, MYC and KRAS have been prime targets for cancer therapy, but their unique characteristics have made them incredibly difficult to inhibit with conventional minor molecule drugs or antibodies. MYC, in particular, is an intrinsically disordered protein, meaning it lacks a fixed three-dimensional structure, making it hard to target with drugs designed to bind to specific shapes. KRAS, while having a more defined structure, undergoes frequent mutations that alter its shape and function, rendering many drugs ineffective. Northwestern Now News highlighted the significance of overcoming these challenges.
How Bionic Biologics Perform
Grove Biopharma’s approach utilizes protein-like polymers (PLPs) that are designed to be bifunctional. This means they can simultaneously engage with the target protein – MYC or KRAS – and recruit the cell’s own protein degradation machinery, specifically the ubiquitin-proteasome system. This system acts like a cellular “trash compactor,” identifying and breaking down unwanted proteins. By hijacking this natural process, the PLPs effectively eliminate the cancer-driving proteins. The company’s platform integrates advances in synthetic precision polymerization, computational protein engineering, and medicinal chemistry to create these protein-scale molecules.
Preclinical Study Results
The Nature Communications study demonstrated that the PLPs were able to selectively degrade MYC in preclinical models. The data showed that the polymers could be engineered to target both MYC and KRAS simultaneously, enhancing their therapeutic potential. This dual-targeting approach could be particularly effective in cancers where both proteins play a role in driving tumor growth. The research team believes this technology could open doors to treating cancers that have historically been resistant to therapy. VentureBeat likewise covered the study’s release.
Implications for Cancer Treatment
The development of PLPs represents a significant advancement in the field of cancer therapeutics. Traditional drug discovery often focuses on finding molecules that bind to and inhibit the activity of target proteins. But, this approach is often unsuccessful for proteins like MYC and KRAS that lack clear binding sites or are prone to mutation. Protein degradation, offers a fundamentally different strategy – eliminating the protein altogether. This approach could potentially overcome drug resistance and provide more durable responses in cancer patients.
“This is a bold mission: to develop scalable, transformative therapeutic modalities for the most intractable intracellular targets,” Grove Biopharma stated in a press release. The company is now focused on advancing this technology towards clinical trials, with the goal of bringing these innovative therapies to patients in need.
The next steps for Grove Biopharma involve further optimizing the PLPs for safety and efficacy, as well as scaling up production for clinical testing. The company anticipates initiating Phase 1 clinical trials within the next 18-24 months, pending regulatory approval. Continued research will also focus on expanding the application of this platform to other challenging cancer targets.
This research offers a beacon of hope in the ongoing fight against cancer, particularly for those cancers driven by proteins that have long been considered beyond the reach of conventional therapies. The development of protein-degrading polymers could usher in a new era of precision medicine, offering more effective and targeted treatments for a wide range of malignancies.
Disclaimer: The information provided in this article is for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have thoughts on this new approach to cancer treatment? Share your comments below, and please share this article with anyone who might find it informative.
